1224844-66-9

Basic information

• Product Name: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)benzo[d]oxazol-2-amine
• Synonyms: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)benzo[d]oxazol-2-amine;2-aminobenzo[d]oxazol-5-ylboronic acid pinacol ester;5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzoxazol-2-amine;2-Benzoxazolamine, 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
• CAS NO: 1224844-66-9
• Molecular Formula: C₁₃H₁₇BN₂O₃
• Molecular Weight: 260.1
• Mol File: 1224844-66-9.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 411.7±37.0 °C(Predicted)
• Appearance: /
• Density: 1.19±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.75±0.10(Predicted)
• CAS DataBase Reference: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)benzo[d]oxazol-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)benzo[d]oxazol-2-amine(1224844-66-9)
• EPA Substance Registry System: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)benzo[d]oxazol-2-amine(1224844-66-9)

Safety Data

• Hazardous Substances Data: 1224844-66-9(Hazardous Substances Data)

Usage

Description

5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)benzo[d]oxazol-2-amine is a complex organic compound characterized by its unique molecular structure. It is a derivative of benzo[d]oxazol-2-amine, featuring a 1,3,2-dioxaborolan-2yl group as a substituent. 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)benzo[d]oxazol-2-amine is known for its potential applications in the pharmaceutical and chemical industries due to its versatile chemical properties.

Uses

Used in Pharmaceutical Industry:
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)benzo[d]oxazol-2-amine is used as a key intermediate in the synthesis of small-molecular inhibitors, specifically targeting the mTOR pathway. This application is significant because mTOR (mechanistic target of rapamycin) is a protein kinase that plays a crucial role in regulating cell growth, proliferation, and survival. Inhibition of the mTOR pathway has been shown to be effective in treating various types of cancer.
The compound serves as a building block for the development of mTOR inhibitors, which can potentially be used in the treatment of cancer. By targeting the mTOR pathway, these inhibitors can help to suppress tumor growth and proliferation, offering a promising therapeutic approach for cancer patients.

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 64037-07-6 5-bromo-1,3-benzoxazol-2-amine 
• 1404480-03-0 C₇H₇BrN₂OS 
• 7693-52-9 4-bromo-2-nitrophenol 
• 106-41-2 4-bromo-phenol 
• 40925-68-6 2-amino-4-bromo-phenol 

Downstream Products

• 1404480-15-4 2-amino-benzooxazole-5-boronic acid hydrochloride 
• 1268454-23-4 (6-(2-aminobenzo[d]oxazol-5-yl)imidazo[1,2-a]pyridin-3-yl)(morpholino)methanone 
• 1224844-38-5 INK128 
• 1395145-15-9 2-(4-(8-(2-aminobenzo[d]oxazol-5-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitril 

Relevant articles and documents

Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a major contributor to global cancer incidence and mortality. Many pathways are involved in the development of HCC and various proteins including mTOR and HDACs have been identified as potential drug targets for HCC treatment. In the present study, two series of novel hybrid molecules targeting mTOR and HDACs were designed and synthesized based on parent inhibitors (MLN0128 and PP121 for mTOR, SAHA for HDACs) by using a fusion-type molecular hybridization strategy. In vitro antiproliferative assays demonstrated that these novel hybrids with suitable linker lengths exhibited broad cytotoxicity against various cancer cell lines, with significant activity against HepG2 cells. Notably, DI06, an MLN0128-based hybrid, exhibited antiproliferative activity against HepG2 cells with an IC50 value of 1.61 μM, which was comparable to those of both parent drugs (MLN0128, IC50 = 2.13 μM and SAHA, IC50 = 2.26 μM). In vitro enzyme inhibition assays indicated that DI06, DI07 and DI17 (PP121-based hybrid) exhibited nanomolar inhibitory activity against mTOR kinase and HDACs (e.g., HDAC1, HDAC2, HDAC3, HADC6 and HADC8). Cellular studies and western blot analyses uncovered that in HepG2 cells, DI06 and DI17 induced cell apoptosis by targeting mTOR and HDACs, blocked the cell cycle at the G0/G1 phase and suppressed cell migration. The potential binding modes of the hybrids (DI06 and DI17) with mTOR and HDACs were investigated by molecular docking. DI06 displayed better stability in rat liver microsomes than DI07 and DI17. Collectively, DI06 as a novel mTOR and HDACs inhibitor presented here warrants further investigation as a potential treatment of HCC.

5 - Pyridyl -2 - amino - benzo [d] oxazole derivative and its preparation and use (by machine translation)

The present invention discloses the general formula (I) indicated by the 5 - pyridyl - 2 - amino - benzo [d] oxazole derivative or its pharmaceutically acceptable salt, its preparation method, pharmaceutical composition and use: According to the compounds of this invention can be used for preparing the treatment of cervical cancer, breast cancer, stomach cancer, liver cancer, renal carcinomas of the drug. (by machine translation)

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.